Hologenix, Celliant’s parent company, formed the Science Advisory Board in 2011 to further establish itself as the leader in responsive textiles. Hologenix works in partnership with the Board to identify, design and execute rigorous clinical studies to further validate and substantiate our significant claims in the field of infrared technology. Celliant’s Science Advisory Board is composed of experts from the fields of photobiology, nanotechnology, sleep medicine, and diabetes and wound care.
With over 30 years of experience, Dr. Hamblin is the Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital and is an Associate Professor of Dermatology at Harvard Medical School. He is also a member of the affiliated faculty of the Harvard-MIT Division of Health Science and Technology. Dr. Hamblin also chairs Mechanisms for Low-Light Therapy, an annual conference at SPIE Photonics West.
Dr. Weiss is the Dean M. Willard Chair in Chemistry and Professor of Chemistry and Biochemistry, Physical Chemistry, and Physiology and a member of the California NanoSystems Institute at UCLA. He has been a scientific researcher for over 20 years, both in and out of the university. The Weiss lab has worked on ultrasensitive single molecule spectroscopy methods for over 15 years, and was the first to introduce the single molecule FRET method and were among the first to introduce quantum dots to biological imaging.
Dr. Drake is the Chairman of the National Sleep Foundation and the Bioscientific Staff Investigator at the Henry Ford Hospital Sleep Disorders Research Center. Dr Drake is also Associate Professor of Psychiatry and Behavioral Neurosciences at the School of Medicine, Wayne State University. Along with authoring over 150 articles, reviews and abstracts in his field, Dr. Drake serves on the editorial board of the journals Sleep, The Open Sleep Journal, and Behavioral Sleep Medicine.